tbc-1269
Small moleculeexperimental
Clinical trial activity
3 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started Jan 14, 2009 (NCT00823693)
Timeline
2000s
- Jan 1, 2009
Earliest Phase 2 Sponsor(trial)
Indications
Mechanism of action
Chemistry & pharmacology
Loading structure…
SMILES
O=C(O)Cc1cccc(-c2cc(CCCCCCc3ccc(O[C@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@@H]4O)c(-c4cccc(CC(=O)O)c4)c3)ccc2O[C@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@@H]2O)c1- Mol. weight
- 862.92 g/mol
- Lipinski Ro5
- 3 violation(s)
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL1215923 ↗
Also known as
- 1,6-bis(3-(3-carboxymethylphenyl)-4-(2-alpha-d-mannopyranosyloxy)phenyl)hexane
- bimosiamose
- bimosiamose
- bimosiamose
- bimosiamose
- bimosiamose disodium
- tbc 1269
- tbc-1269
- tbc-1269
- tbc-1269
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01108913 | Phase 2 | Apr 21, 2010 | Encysive |
| NCT00962481 | Phase 2 | Aug 19, 2009 | Encysive |
| NCT00823693 | Phase 2 | Jan 14, 2009 | Encysive |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Encysive | For profit | 3 | 3 | 1 | 2009 |
1 organizations
Page 1 / 1